Home/AAVogen/Jade Brown, MBA

JB

Jade Brown, MBA

Business Development Director

Therapeutic Areas

Muscle Wasting Diseases Neuromuscular Diseases Cardiovascular Disease

AAVogen Pipeline

Drug	Indication	Phase
AVGN7	Inclusion Body Myositis (IBM)	Pre-clinical
AVGN7 + AVGND	Duchenne Muscular Dystrophy (DMD)	Pre-clinical

Leadership Team at AAVogen

Buel "Dan" Rodgers, PhD

Alexandra McPherron, PhD

Chief Scientific Officer (CSO)

Chris Novashinski

Regulatory Affairs Director, Co-Founder & COO (RareMoon)

Joseph Rininger, PhD

Gary Carswell, CPA

CFO (contracted)

View full AAVogen profile